Home › Therapeutic areas › Neurology › Parkinson's Disease
Parkinson's Disease (13 companies)
Companies with an active program in Parkinson's Disease.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACIU | AC Immune | Neurology Rare | 2 | Phase 3 | $222M | 11 |
| ATHE | Alterity Therapeutics | Neurology Rare | 1 | Phase 2 | $46.4M | 2 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | $420M | 10 |
| CLNN | Clene | Neurology Rare | 1 | NDA Submitted | $56.9M | 5 |
| GANX | Gain Therapeutics | MetabolicNeurology Rare | 2 | Phase 1 | $45.0M | 5 |
| MPLT | MapLight Therapeutics | Neurology | 1 | Phase 2 | $385M | 6 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 1 | Phase 3 | $864M | 16 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 1 | Phase 2 | $3.2M | 3 |
| OMER | Omeros | HematologyNeurology+2 Rare | 1 | Approved | $1.22B | 6 |
| PMN | ProMIS Neurosciences | Neurology Rare | 1 | Phase 1 | $37.3M | 6 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+2 Rare | 1 | Phase 3 | $4.8M | 10 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | $231M | 27 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 1 | Phase 1 | $116M | 9 |
No companies match.